How Lewis was paid
$1.2M in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Other | Total |
|---|---|---|---|---|---|
| Joel LewisChief Executive Officer & President | $620,167 | $312,000 | $202,635 | $54,872 | $1,189,674 |
| Khurram Jamil, M.D.Chief Medical Officer | $365,909 | $120,625 | $398,500 | $60,813 | $945,847 |
| Jack W. CallicuttChief Financial Officer | $397,333 | $120,000 | $144,740 | $54,872 | $716,945 |
What changed and why
- $1.2M$1,189,674 was CEO total compensation in 2024 versus $963,647 in 2023.
- $312K$312,000 bonus and $202,635 stock compensation awards were included in the CEO’s 2024 compensation.
- $946K$945,847 was Chief Medical Officer Khurram Jamil’s 2024 total compensation after joining in March.
- 80%80% of Lewis’s salary and bonus were awarded in deferred stock units through December 31, 2023.
- 90%90% of votes cast supported NEO compensation at the 2022 say-on-pay vote.
- The Compensation Committee targeted at least the 50th percentile of competitor total compensation programs.
Other Galectin Therapeutics proxy statements
- 2026 proxy statement
Joel Lewis paid $1.2M (-1% on the year).
Filed Oct 13, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.